| Market Cap | 10.1B 8.83B 8.14B 7.55B 14.33B 958B 14.56B 97.63B 37.97B 473B 37.9B 37.08B 1,634B | P/E 2026 * |
179x | P/E 2027 * | 39x |
|---|---|---|---|---|---|
| Enterprise Value | 9.88B 8.65B 7.97B 7.39B 14.02B 938B 14.25B 95.56B 37.16B 463B 37.1B 36.3B 1,600B | EV / Sales 2026 * |
9.82x | EV / Sales 2027 * | 6.87x |
| Free-Float |
65.96% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Corcept Therapeutics
| 1 day | +0.16% |
| Manager | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
CEO | Chief Executive Officer | 68 | 31/12/1998 |
Atabak Mokari
DFI | Director of Finance/CFO | 49 | 28/02/2021 |
Joseph Lyon
CTO | Chief Tech/Sci/R&D Officer | 48 | 31/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Belanoff
BRD | Director/Board Member | 68 | 31/12/1998 |
Gregg Alton
BRD | Director/Board Member | 60 | 11/03/2020 |
George Baker
BRD | Director/Board Member | 83 | 31/12/1998 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.16% | +13.02% | - | - | 10.1B | |
| +2.96% | +3.01% | +59.87% | +173.31% | 1,102B | |
| +3.05% | +5.23% | +72.11% | +67.81% | 643B | |
| -0.04% | +1.20% | +35.72% | +87.93% | 450B | |
| +0.62% | -2.07% | +27.62% | +22.57% | 336B | |
| -1.03% | -0.87% | +28.55% | +47.78% | 288B | |
| -3.05% | +1.06% | -27.94% | -40.79% | 222B | |
| +0.45% | +1.65% | +25.65% | +68.35% | 199B | |
| +5.21% | +7.93% | +21.99% | +83.23% | 169B | |
| +1.48% | -0.04% | -4.64% | -32.25% | 137B | |
| Average | +0.04% | +2.00% | +26.55% | +53.10% | 393.9B | |
| Weighted average by Cap. | +0.17% | +1.86% | +41.72% | +87.35% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.01B 880M 811M 752M 1.43B 95.49B 1.45B 9.73B 3.78B 47.12B 3.78B 3.7B 163B | 1.4B 1.23B 1.13B 1.05B 1.99B 133B 2.02B 13.54B 5.27B 65.58B 5.26B 5.14B 227B |
| Net income | 85.73M 75.02M 69.14M 64.08M 122M 8.14B 124M 829M 322M 4.02B 322M 315M 13.88B | 369M 323M 297M 276M 523M 34.98B 531M 3.56B 1.39B 17.26B 1.38B 1.35B 59.67B |
| Net Debt | -213M -187M -172M -160M -303M -20.25B -308M -2.06B -802M -9.99B -801M -784M -34.55B | -474M -415M -382M -354M -673M -45.01B -684M -4.59B -1.78B -22.21B -1.78B -1.74B -76.77B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
